Overactive bladder/enuresis:

Indications for: VESICARE

Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Adult Dosage:

Swallow whole with water. Initially 5mg once daily; if well tolerated, may increase to 10mg once daily. Severe renal impairment (CrCl <30mL/min/1.73m2), moderate hepatic impairment (Child-Pugh B), or concomitant strong CYP3A4 inhibitors: max 5mg once daily.

Children Dosage:

Not established.

VESICARE Contraindications:

For tabs: urinary retention. For tabs & susp: gastric retention, uncontrolled narrow-angle glaucoma.

VESICARE Warnings/Precautions:

Significant bladder outlet obstruction, decreased GI motility, high risk or history of QT prolongation, severe hepatic impairment (Child-Pugh C): not recommended. Controlled narrow-angle glaucoma. Monitor for CNS effects esp. after initiation or dose increases; consider dose reduction or discontinuation if occurs. Severe renal or moderate hepatic impairment. Pregnancy. Nursing mothers.

See Also:

VESICARE Classification:

Muscarinic antagonist.

VESICARE Interactions:

Potentiated by strong CYP3A4 inhibitors (eg, ketoconazole). May be antagonized by CYP3A4 inducers. Avoid drugs known to prolong the QT interval. Additive anticholinergic effects with other anticholinergics.

Adverse Reactions:

Dry mouth, constipation, UTI, blurred vision; CNS effects (eg, headache, confusion, hallucination, somnolence); angioedema and anaphylactic reactions (discontinue if occurs).

Generic Drug Availability:


How Supplied:

Tabs—30, 90; Susp—150mL